Smell Recovery Breakthrough Could Speed Things Up
- 01. Smell recovery research is showing real progress, and the latest findings suggest recovery may be faster and more treatable than many doctors once thought.
- 02. What changed in the research
- 03. Latest findings in treatments
- 04. How the biology is being reframed
- 05. What patients can expect
- 06. What experts are watching next
- 07. Frequently asked questions
Smell recovery research is showing real progress, and the latest findings suggest recovery may be faster and more treatable than many doctors once thought.
Recent studies point to a clearer path for people with persistent smell loss: start with smell training and steroid irrigation, then escalate to specialist therapies such as platelet-rich plasma, surgical airflow correction in selected cases, and experimental neuromodulation or device-based approaches. The strongest new signal is that smell recovery is not always a passive waiting game; in several cohorts, targeted treatment is producing measurable improvement, including a Mayo Clinic summary that reported clinically significant gains after platelet-rich plasma therapy in 87% of treated patients at one year.
What changed in the research
The biggest shift in smell recovery research is the move away from treating every case as the same problem. Scientists now see multiple biological pathways behind anosmia and hyposmia, including injury to olfactory sensory neurons, inflammation, disrupted support cells, and airflow problems that keep odor molecules from reaching the olfactory cleft. That matters because a treatment that helps one subtype may do little for another, which is why recent papers increasingly focus on matching therapy to cause rather than using a one-size-fits-all approach.
COVID-19 accelerated that change by revealing that smell loss can come from damage to sustentacular cells, the support cells that help keep olfactory tissue healthy, not only from direct neuron injury. That insight helped researchers understand why some people recovered quickly while others had symptoms for months or years, and why formal smell testing can detect ongoing loss that patients may not notice themselves. In a RECOVER cohort published in 2025, 79.8% of people who reported smell change or loss had confirmed hyposmia on testing, while a large group without self-reported symptoms still had measurable dysfunction.
Latest findings in treatments
Several treatment directions now stand out in current research, especially for long-lasting post-viral smell loss. Olfactory training remains the foundation, and Mayo Clinic's review said it improves smell in about 26% of people with anosmia, while adding nasal steroid irrigation can raise recovery to about 50%. These figures are not a cure, but they matter because they define a realistic first-line strategy that is low risk and accessible.
- Olfactory training: repeated exposure to a set of odors to retrain smell pathways, with benefit in about 26% of people with anosmia in one summary.
- Nasal steroid irrigation: steroid rinses used with training, which Mayo Clinic said can roughly double recovery rates to about 50%.
- Platelet-rich plasma: an emerging office-based therapy that showed clinically significant improvement at one year in 87% of treated patients in a summarized study.
- Functional septorhinoplasty: a surgical option for selected patients whose smell loss is linked to poor nasal airflow, with improvement reported in long-COVID patients who failed other treatments.
- Device-based approaches: early-stage research is testing systems that translate odors into coded signals to help the brain distinguish scents again.
The most talked-about breakthrough is platelet-rich plasma, or PRP. In the Mayo Clinic discussion of evolving anosmia treatment, PRP was described as a promising option because it carries anti-inflammatory and growth factors that may help damaged olfactory neurons recover, and one cited study found meaningful improvement one year after treatment in 87% of patients. That does not yet make PRP standard care, but it does mark a serious advance beyond purely supportive management.
Another notable finding is that surgery may help when the problem is partly mechanical. In 2025, UCL researchers reported that functional septorhinoplasty improved smell in long-COVID patients with persistent olfactory dysfunction, especially when standard approaches such as smell training and corticosteroids had not worked. This supports a more practical view of smell recovery: if odor molecules cannot reach the right tissue efficiently, restoring airflow can improve sensory input.
How the biology is being reframed
Researchers now describe smell loss as a mix of neural, inflammatory, and structural problems rather than a single diagnosis. That distinction helps explain why some people feel "back to normal" while still testing below normal on smell exams, and why others report a normal nose but struggle with smoke, spoiled food, or flavor perception in daily life. The RECOVER data are especially important because they show occult or unrecognized smell loss is common after SARS-CoV-2 infection and may justify earlier testing and counseling.
There is also increasing interest in regeneration. A 2026 Medscape summary highlighted new investigational therapies, including olfactory training, PRP injections, and neuromodulation approaches, while noting that the field is still early and none of these methods are yet routine standard care. That cautious language matters: the science is advancing, but many of the most exciting ideas are still being tested in small studies or early clinical models.
| Approach | What it targets | Current evidence signal | Practical status |
|---|---|---|---|
| Olfactory training | Neural retraining and odor recognition | About 26% improvement in anosmia in one summary | Common first-line option |
| Nasal steroid irrigation | Inflammation | Reported recovery of about 50% when combined with training | Used in specialist care |
| PRP therapy | Tissue repair and inflammation | 87% clinically significant improvement at one year in a cited study | Promising but not universal standard |
| Functional septorhinoplasty | Airflow obstruction | Improved smell in selected long-COVID patients | Best for structural cases |
| Odor-coded device systems | Brain signaling and sensory substitution | Early human testing in 65 participants, with odor detection and discrimination possible | Experimental |
What patients can expect
For people asking whether smell can come back, the answer is often yes, but the timeline depends on the cause, severity, and treatment response. One 2025 article from the Institute of Optics and associated commentary said many people recover within months after infection, while a minority still have symptoms at one year. In practical terms, that means the first few months matter most for conservative therapy, but persistent loss beyond that window increasingly justifies specialist evaluation.
Doctors are also becoming more aggressive about identifying hidden loss because it carries safety and quality-of-life risks. The RECOVER study noted that people with smell dysfunction may not realize how reduced their sense is, which can affect their ability to detect smoke, gas, or spoiled food. That is one reason formal smell tests are gaining favor in post-viral care: they can reveal impairment even when patients think they are improving.
- Start with a smell test or specialist assessment if loss lasts more than several weeks.
- Use smell training consistently, usually with structured odor exposure over months.
- Consider steroid irrigation if inflammation or post-viral injury is suspected.
- Escalate to an ear, nose, and throat specialist if symptoms persist beyond about six months.
- Ask about PRP, surgery, or trials only after the cause is better defined.
What experts are watching next
The next wave of research is likely to focus on precision treatment, not just symptom relief. Scientists want to know which patients benefit from anti-inflammatory treatment, which need airflow correction, and which may respond best to biologic repair therapies like PRP. At the same time, experimental work on sensory substitution and neuromodulation could eventually help patients whose olfactory tissue is too damaged to recover in the usual way.
"The answer may be platelet-rich plasma therapy," the Mayo Clinic summary said, while stressing that olfactory training and nasal steroid irrigation remain the best-supported current approach for many patients.
That quote captures the current state of the field well: the old story was "wait and hope," but the new story is "test, classify, train, and treat more precisely." The most credible latest findings do not promise instant cures, yet they do show that smell recovery is becoming more measurable, more biologically grounded, and more treatable than it was only a few years ago.
Frequently asked questions
Expert answers to Smell Recovery Breakthrough Could Speed Things Up queries
Can smell loss really recover after COVID-19?
Yes, many people recover, but the time course varies, and formal testing often reveals more dysfunction than patients realize.
What is the most supported treatment right now?
Olfactory training, often combined with nasal steroid irrigation, has the best current support among widely used therapies.
Is platelet-rich plasma proven?
Not fully; it is promising and has shown strong improvement signals in recent studies, but it is still not a universal standard treatment.
When should someone see a specialist?
If smell loss lasts for months, interferes with safety or eating, or does not improve with basic therapy, specialist evaluation is warranted.
Are there any non-drug options?
Yes, smell training is the main non-drug strategy, and surgery may help when structural airflow problems are contributing.